Skip to content

High Flow Nasal Cannula Dose Finding Study in Neonatal Intensive Care

What is the effect of different delivered flow rates on the work of breathing in infants requiring respiratory support?

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12615001069549
Acronym
HiFiDo
Enrollment
29
Registered
2015-10-13
Start date
2016-05-29
Completion date
2019-12-31
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Delivery of air flow by high flow nasal cannula (HFNC) has become increasingly popular in neonatal and paediatric intensive care units throughout Australia and the world. Despite this, there is limited knowledge on how to determine the most appropriate flow rate for the infant. This study will measure the electrical activity of the diaphragm to determine when the work of breathing is optimal and then examine what other physiological measures correlate with this. The aim of this study is to demonstrate the physiological effect of randomly applied levels of high flow on the work of breathing (WOB) indirectly measured with electric diaphragmatic activity. Methods: This is a prospective interventional study of premature infants with respiratory distress admitted to the Neonatal Critical Care Unit (NCCU), Mater Mothers Hospital, South Brisbane and infants with bronchiolitis admitted to Lady Cilento Childrens Hospital (LCCH). Work of breathing (WOB) will be measured with diaphragmatic electrical activity - measured transoesophageal (Edi)and transdermal (Tdi), and respiratory inductance plethysmography (RIP). Using the Edi signals we will measure the WOB during HFNC treatment and assess its impact on patients with respiratory distress. Edi requires inserting a specially designed sensing nasogastric tube into the infants’ nose, Tdi involves placing five regular skin elecrodes on the chest, and RIP consists of two stretch bands placed around the chest and abdomen. Both Edi and RIP signal can be recorded continuously during the entire study period and recorded on a dedicated computer and further analysed. Physiological variables of respiratory rate (RR), heart rate (HR), and oxygen saturations (SpO2) will also be monitored throughout the study. From the collected data the SpO2/FiO2 ratio will be calculated. Study Procedure: Infants recruited into the trial will be on HFNC oxygen therapy using the Fisher & Paykel 850 humidifier. The in situ nasogastric tube will be replaced by the Edi probe. The first measurement will be done when the infant is settled but within the first 24 hours of HFNC administration. Thereafter, flow rates between 2 and 8 L /min will be randomly applied for the preterm infant and between 0.5 L/kg/min and 2 L/kg/min for the infants with bronchiolitis. At the conclusion, initial HFNC settings will be reinstituted.

Interventions

High flow nasal cannula will be delivered to infants with flow rates randomly applied. For preterm infants the flow rates will be between 2L/min and 8L/min in 2L steps. For infants with bronchiolitis, flow rates between 0.5 L/kg/min and 2 L/kg/min will be randomly applied in 0.5 L/Kg/min steps. After each flow rate change an equilibration phase of 10 minutes will be allowed before undertaking a 5 minute measurement. Each of the 4 flow rates will be applied for 15 minutes. The total study duratio

High flow nasal cannula will be delivered to infants with flow rates randomly applied. For preterm infants the flow rates will be between 2L/min and 8L/min in 2L steps. For infants with bronchiolitis, flow rates between 0.5 L/kg/min and 2 L/kg/min will be randomly applied in 0.5 L/Kg/min steps. After each flow rate change an equilibration phase of 10 minutes will be allowed before undertaking a 5 minute measurement. Each of the 4 flow rates will be applied for 15 minutes. The total study duration will be 2 hours.

Sponsors

Mater Health Services
Lead SponsorHospital

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
No minimum to 12 Months
Healthy volunteers
No

Inclusion criteria

Preterm group Infants at 28 – 36 weeks corrected gestational age Are currently treated with nCPAP Are currently deemed stable enough by the treating medical and nursing staff to go onto HFNC Have an FiO2 requirement less than or equal to 0.40 Nasogastric (ng) feeding tube in place Parent(s) or guardian able and willing to provide informed consent Bronchiolitis group Clinical diagnosis of bronchiolitis with increased WOB (retraction, auxiliary respiratory muscle use) and respiratory distress due to viral infection An oxygen requirement treated with high flow in ICU Aged 0-12 months Nasogastric (ng) feeding tube in place Parent(s) or guardian able and willing to provide informed consent

Exclusion criteria

Lung or cardiovascular anomaly that would substantially affect oxygenation, lung recruitment or regional ventilation, e.g.; Cyanotic or other major congenital heart disease (not including Patent Ductus Arteriosus) Craniofacial malformations or congenital disease affecting the respiratory system More than 2 episodes within the last hour of apnoea and/or bradycardia requiring moderate or vigorous stimulation and an increase in FiO2 or change in CPAP pressure

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026